Name | α-Glucosidase-IN-21 |
---|
Description | α-Glucosidase-IN-21 (Compound 2B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 2.62 μM. α-Glucosidase-IN-21 shows anti-diabetic activity[1]. |
---|---|
Related Catalog | |
In Vivo | α-Glucosidase-IN-21 (Compound 2B; 10 and 20 mg/kg; p.o.; daily, for 4 weeks) has anti-diabetic activity in Streptozocin (HY-13753)-induced diabetic rats[1]. α-Glucosidase-IN-21 (10 and 20 mg/kg; p.o.; once) significantly decreases the serum glucose level after the administration of glucose (3 g/kg, oral) in rats[1]. α-Glucosidase-IN-21 (2000 mg/kg; p.o.; daily, for 2 weeks) demonstrates no mortality in mice[1]. Animal Model: Male Wistar albino rats (170-200 g), Streptozotocin-induced diabetes model[1] Dosage: 10 and 20 mg/kg Administration: Oral administration; daily, for 4 weeks Result: Decreased the level of blood glucose, reversed Streptozocin-induced body weight loss. Showed antihyperlipidemic effects on Streptozotocin-induced diabetes, reduced to a significant level of serum biomarkers. |
References |
Molecular Formula | C24H23NO2S |
---|---|
Molecular Weight | 389.51 |